25637145|t|Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients.
25637145|a|Amyotrophic lateral sclerosis (ALS) is an adult-onset disease characterized by the selective degeneration of motor neurons in the brain and spinal cord progressively leading to paralysis and death. Current diagnosis of ALS is based on clinical assessment of related symptoms. The clinical manifestations observed in ALS appear relatively late in the disease course after degeneration of a significant number of motor neurons. As a result, the identification and development of disease-modifying therapies is difficult. Therefore, novel strategies for early diagnosis of neurodegeneration, to monitor disease progression and to assess response to existing and future treatments are urgently needed. Factually, many neurological disorders, including ALS, are accompanied by skin changes that often precede the onset of neurological symptoms. Aiming to generate an innovative human-based model to facilitate the identification of predictive biomarkers associated with the disease, we developed a unique ALS tissue-engineered skin model (ALS-TES) derived from patient's own cells. The ALS-TES presents a number of striking features including altered epidermal differentiation, abnormal dermo-epidermal junction, delamination, keratinocyte infiltration, collagen disorganization and cytoplasmic TDP-43 inclusions. Remarkably, these abnormal skin defects, uniquely seen in the ALS-derived skins, were detected in pre-symtomatic C9orf72-linked ALS patients carrying the GGGGCC DNA repeat expansion. Consequently, our ALS skin model could represent a renewable source of human tissue, quickly and easily accessible to better understand the physiophatological mechanisms underlying this disease, to facilitate the identification of disease-specific biomarkers, and to develop innovative tools for early diagnosis and disease monitoring.
25637145	19	43	structural abnormalities	Disease	MESH:C566527
25637145	76	82	TDP-43	Gene	23435
25637145	123	126	ALS	Disease	MESH:D000690
25637145	127	135	patients	Species	9606
25637145	137	166	Amyotrophic lateral sclerosis	Disease	MESH:D000690
25637145	168	171	ALS	Disease	MESH:D000690
25637145	314	323	paralysis	Disease	MESH:D010243
25637145	328	333	death	Disease	MESH:D003643
25637145	356	359	ALS	Disease	MESH:D000690
25637145	453	456	ALS	Disease	MESH:D000690
25637145	707	724	neurodegeneration	Disease	MESH:D019636
25637145	851	873	neurological disorders	Disease	MESH:D009461
25637145	885	888	ALS	Disease	MESH:D000690
25637145	1010	1015	human	Species	9606
25637145	1137	1140	ALS	Disease	MESH:D000690
25637145	1171	1174	ALS	Disease	MESH:D000690
25637145	1193	1200	patient	Species	9606
25637145	1218	1221	ALS	Disease	MESH:D000690
25637145	1427	1433	TDP-43	Gene	23435
25637145	1473	1485	skin defects	Disease	MESH:D012868
25637145	1508	1511	ALS	Disease	MESH:D000690
25637145	1559	1566	C9orf72	Gene	203228
25637145	1574	1577	ALS	Disease	MESH:D000690
25637145	1578	1586	patients	Species	9606
25637145	1647	1650	ALS	Disease	MESH:D000690
25637145	1700	1705	human	Species	9606
25637145	Association	MESH:D000690	203228
25637145	Association	MESH:D000690	23435
25637145	Association	MESH:D012868	203228

